News
The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the pathogenetic role of eosinophils is fundamentally different between asthma ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...
Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.
The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...
14d
Zacks Investment Research on MSNSanofi's Experimental Transplant Rejection Drug Gets FDA Orphan TagSanofi SNY announced that the FDA has granted orphan drug designation to its investigational drug, riliprubart, for the treatment of antibody-mediated rejection (AMR) in solid organ transplantation.
Credit: Toa55/Shutterstock. The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a ...
Alyssa Johnsen, MD, PhD, Global Therapeutic Area Head, Immunology and Oncology Development, Sanofi said, “Until now, treating bullous pemphigoid was very challenging for elderly patients struggling ...
18.3% of patients on Dupixent achieved sustained remission vs. 6.1% on placebo at 36 weeks. Median corticosteroid use was 2.8g with Dupixent vs. 4.1g with placebo in BP patients. From tariffs to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results